Clinical Research

Efficacy/Safety of Talazoparib or Physician’s Choice of Therapy in US Patients with HER2-Negative Germline BRCA1/2-Mutated Locally Advanced/Metastatic Breast Cancer (EMBRACA)

In the COMBI-AD trial (NCT01682083), 12 months of adjuvant D+T led to significant improvement of RFS versus PBO (hazard ratio [HR], 0.47; P <.001) in pts with resected BRAF V600–mutant stage III melanoma; 3- and 4-year RFS rates were 59% and 54%, respectively.

By Sami Diab, MD; Hope S. Rugo, MD; Lida A. Mina, MD; Shannon Puhalla, MD; Reshma Mahtani, DO; N. Lynn Henry, MD, PhD; Neelima Denduluri, MD; Denise Yardley, MD; Yao Wang, MD; Lillian Shahied Arruda, PhD; Iulia C. Tudor, PhD; Eric Gauthier, PharmD, PhD; Akos Czibere, MD, PhD; Jennifer K. Litton, MD; Sara A. Hurvitz, MD

Importance of Collecting Patient-Reported Outcome Measures in Oncology Clinical Research

Talazoparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the US for HER2-negative germline BRCA1/2-mutated (gBRCA1/2mut) locally advanced/metastatic breast cancer.

By Leona Hamrick, DHSc, PA-C; Kate Smith, MPH; Susan Thompson

Late Dosing of Luteinizing Hormone-Releasing Hormone Agonists and Testosterone Levels >20 ng/dL in Prostate Cancer

Evidence exists showing that enabling patients to engage in treatment decisions through education and shared decision-making is an effective tool in promoting self-efficacy, reducing barriers to care, and increasing the perceived benefits of self-involvement in one’s cancer diagnosis and treatment plan.

By Julia Vandross, NP-BC, BSN, MSN; Stuart N. Atkinson, MB, ChB; Deborah M. Boldt-Houle, PhD; Tina DeNofrio, RN, BSN, OCN

Managing Adverse Events in Patients with Relapsed/Refractory Mantle Cell Lymphoma Treated with Acalabrutinib: Clinical Experience from MD Anderson Cancer Center

Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used drugs for the delivery of androgen deprivation therapy (ADT) in prostate cancer (PCa).

By Maria Badillo, MSN, RN; Diana Nava, RN; Maria de la Rosa; Wendy Chen, PA; Maria Guerrero, DNP, MS, RN; Michael Wang, MD

Nursing Best Practices for Moxetumomab Pasudotox-tdfk, a New Treatment for Hairy Cell Leukemia

Acalabrutinib is a highly selective, potent, covalent Bruton tyrosine kinase inhibitor, approved for use in adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL), an aggressive B-cell malignancy.

By Kathleen Reed, RN, MS, AOCNS; Cynthia Elesinmogun, PharmD; Sheetal Desai, PharmD, BCOP

Nursing Experience in Patients Receiving Long-Term Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Final Analysis Results from Phase 3 RESONATE Study

Hairy cell leukemia (HCL) is a rare B-cell malignancy, diagnosed in ~1000 new patients a year in the US.

By Jillian Settlemire, RN; Jocelyn E. Bushart, ANP-BC; Sandra Dai, PhD, MS; James P. Dean, MD, PhD; David Arthur, PhD; Paul Barr, MD; Steven Coutre, MD

Oncology Nursing Experience in Phase 3 iLLUMINATE: First-Line Ibrutinib-Obinutuzumab Versus Chlorambucil-Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase (BTK), is approved in the US for the treatment of CLL/SLL and allows for treatment without chemotherapy.

By Shelbi Burtt BSN, RN, OCN; Jessica Scott, RN, BSN, OCN; Cathy Zhou, MS; Lori Styles, MD; David Arthur, PhD; Bertrand Anz, MD; Ian W. Flinn, MD, PhD

Treatment Adherence and Proactive Adverse Event Management for Adjuvant Targeted Therapy in Patients with Resected Stage III Melanoma

Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase, is approved in the US for CLL/SLL treatment, including in combination with obinutuzumab.

By Jeanelle King, PA-C; Suzanne McGettigan, MSN, CRNP, AOCN; Virginia Seery, CRNP, MSN